Ouro Medicines-preview

Ouromedicines

Ouro Medicines

Private

South San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.ouromedicines.com/

Last Round

Series A

Jan 10, 2025

Total Funding Raised

$120M

Momentum Score

50 /100

Company Overview

Ouro Medicines is a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

T cell engagersbispecific T cell engagerTCEsB cell depletionautoimmune disease therapeuticsimmune resetbispecific antibodyBCMA-directed therapyimmunotherapyclinical-stage biotechB cell biologydrug discoveryautoimmune cytopeniasAICSjögren's diseaseidiopathic inflammatory myopathyIIM

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ouro Medicines Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Ouro Medicines Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	Jan 10, 2025

View all Funding Rounds

Key People

Founding team and executive leadership

Jaideep Dudani

CEO

Executive Team

Christina Carlson

General Counsel And Chief Operating Officer, General Counsel And Chief Administrative Officer

Executive Team

Ouro Medicines Investors

Notable investors and investment history

Investor	Rounds
TPG Life Sciences Innovations	Series A
Boyu Capital	Series A
New Enterprise Associates (NEA)	Series A
Monograph Capital	Series A
Norwest Venture Partners	Series A
LongRiver Investments	Series A
UPMC Enterprises	Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 20, 2026
Monthly visitors grew 126% MoM, reaching 5K.
Mar 31, 2026
Galapagos NV acquired operational assets, including drug candidate gamgertamig and preclinical programs.

View all signals

Ouro Medicines Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Ouro Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ouro Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California

Employee Range25

Year Founded2024

Last FundingJan 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.